Anatara Lifesciences Ltd (AU:ANR) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Anatara Lifesciences has paused recruitment for its GaRP-IBS clinical trial after exceeding participant targets, with results expected in March 2025. The company is also offering a Share Purchase Plan to raise funds for this trial and an anti-obesity project. This strategic move could intrigue investors interested in the biotech sector as it positions the company for upcoming developments.
For further insights into AU:ANR stock, check out TipRanks’ Stock Analysis page.